10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CD225 Antibody
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP53303

Specification

CD225 Antibody - Product Information

Application	**WB**
Primary Accession	P13164
Reactivity	**Human**
Host	**Rabbit**
Clonality	**Polyclonal**
Calculated MW	**14 KDa**
Antigen Region	**1-50**

CD225 Antibody - Additional Information

Gene ID 8519

Other Names
Interferon-induced transmembrane protein 1, Dispanin subfamily A member 2a, DSPA2a, Interferon-induced protein 17, Interferon-inducible protein 9-27, Leu-13 antigen, CD225, IFITM1, CD225, IFI17

Dilution
WB~~ 1:500

Format
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.09% (W/V) sodium azide and 50% glycerol

Storage
Store at -20 °C.Stable for 12 months from date of receipt

CD225 Antibody - Protein Information

Name IFITM1 (HGNC:5412)

Synonyms CD225, IFI17

Function
IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) (PubMed:26354436, PubMed:33270927). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-

mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration (PubMed:33270927). Inhibits SARS-CoV-2 S protein- mediated syncytia formation (PubMed:33051876). Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436).

Cellular Location
Cell membrane; Single-pass membrane protein. Lysosome membrane

Tissue Location
Bone (at protein level). Levels greatly elevated in colon cancer, cervical cancer, esophageal cancer and ovarian cancer Expressed in glioma cell lines.

CD225 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

CD225 Antibody - Images



10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-CD225 Antibody at 1:500 dilution + Hela whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L),Peroxidase conjugated at 1/10000 dilution. Predicted band size : 14 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

CD225 Antibody - Background

IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronavirus (SARS-CoV), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). Can inhibit: influenza virus hemagglutinin protein- mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation.

CD225 Antibody - References

Reid L.E.,et al.Proc. Natl. Acad. Sci. U.S.A. 86:840-844(1989).
Deblandre G.A.,et al.J. Biol. Chem. 270:23860-23866(1995).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Taylor T.D.,et al.Nature 440:497-500(2006).